Revance Therapeutics Stock Fair Value Calculation – Mizuho Sets $16.00 Price Target for Revance Therapeutics
November 25, 2023
🌥️Trending News
Mizuho has set a new price target of $16.00 for Revance Therapeutics ($NASDAQ:RVNC), a biotechnology company focused on developing treatments for aging and aesthetic medicine. The company specializes in botulinum toxin products and has several drug candidates in their pipeline. Revance has made significant progress in its clinical trials and has raised both public and private funds to further develop its drug candidates. They have also signed agreements with several pharmaceutical companies, including Allergan, Ipsen, and Merz, to advance their product development program.
Mizuho has set a price target for Revance based on their assessment of the company’s growth potential. This reflects Mizuho’s confidence in Revance’s future prospects and their ability to bring their drug candidates to market.
Share Price
On Friday, Mizuho set a $16.00 price target for Revance Therapeutics. The stock opened at $7.2 and closed at $7.2, down by 1.2% from the previous closing price of $7.3. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Revance Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 214.16 | -414.24 | -133.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Revance Therapeutics. More…
| Operations | Investing | Financing |
| -204.03 | 148.33 | 132.02 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Revance Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 532.49 | 638.69 | -1.21 |
Key Ratios Snapshot
Some of the financial key ratios for Revance Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 268.5% | – | -185.0% |
| FCF Margin | ROE | ROA |
| -107.5% | 623.7% | -46.5% |
Analysis – Revance Therapeutics Stock Fair Value Calculation
At GoodWhale, we have undertaken a careful analysis of the fundamentals of REVANCE THERAPEUTICS. After making use of our proprietary Valuation Line, we have determined that the fair value of a REVANCE THERAPEUTICS share is around $52.5. What this means in practice is that REVANCE THERAPEUTICS stock is currently undervalued by an astonishing 86.3%, trading at $7.2 instead. More…
Peers
In the realm of aesthetic treatments, there is fierce competition among companies to develop the most innovative and effective products. Among these companies is Revance Therapeutics Inc, which is up against tough competition from Viva Biotech Holdings, Pharmaron Beijing Co Ltd, and CStone Pharmaceuticals. All of these companies are vying to create the best products and treatments that will appeal to consumers.
– Viva Biotech Holdings ($SEHK:01873)
Viva Biotech Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate is VB-111, a first-in-class, targeted anti-cancer agent that is in Phase III clinical development for the treatment of glioblastoma, the most common and aggressive form of brain cancer. Viva Biotech has a market cap of 2.28B as of 2022 and a Return on Equity of 5.39%.
– Pharmaron Beijing Co Ltd ($SZSE:300759)
Pharmaron Beijing Co., Ltd. is a global, research-based drug discovery and development company that partners with life science organizations to transform the way therapeutics are discovered and developed. The company’s services include target identification and validation, lead optimization, preclinical and clinical research, and commercialization. Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China.
– CStone Pharmaceuticals ($OTCPK:CSPHF)
CStone Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapeutics. The company’s market cap is 508.8M as of 2022 and its ROE is -87.18%. CStone Pharmaceuticals is focused on developing and commercializing immuno-oncology therapies that target the tumor microenvironment and modulate the immune system to fight cancer. The company’s lead product candidate, CS1001, is a PD-L1/TGF-β inhibitor that is being evaluated in a global Phase III clinical trial in first-line non-small cell lung cancer.
Summary
Mizuho recently assigned a price target of $16 per share for Revance Therapeutics, Inc. (NASDAQ: RVNC). The investment firm cited the company’s portfolio of novel treatments for facial aesthetics and therapeutic applications as the primary catalyst for its bullish outlook. They remain optimistic about the company’s prospects for continued success in its core markets, as well as potential for new indications in the future.
They also highlighted the fact that Revance has a strong balance sheet with no debt, which provides it with added financial flexibility. Overall, Mizuho believes that the stock is well-positioned for continued upside and remains an attractive investment option.
